litlas
Log inCreate account

Hira Rizvi

Active 2016–2025

61
Papers
21,693
Citations
48
h-index
60
i10-index

Citations

Citations per year for Hira Rizvi1976: 1 citations2005: 1 citations2007: 1 citations2017: 29 citations2018: 244 citations2019: 1,021 citations2020: 1,679 citations2021: 1,771 citations2022: 1,442 citations2023: 1,266 citations2024: 1,771 citations2025: 1,019 citations2026: 43 citations1977–2004: no citations, so these years are not shown2006: no citations, so this year is not shown2008–2016: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,246 citing papers, 24.1% of this breakdownChina: 2,633 citing papers, 19.6% of this breakdownItaly: 779 citing papers, 5.8% of this breakdownFrance: 662 citing papers, 4.9% of this breakdownUnited Kingdom: 609 citing papers, 4.5% of this breakdownGermany: 508 citing papers, 3.8% of this breakdownJapan: 484 citing papers, 3.6% of this breakdownCanada: 407 citing papers, 3% of this breakdownSpain: 399 citing papers, 3% of this breakdownAustralia: 312 citing papers, 2.3% of this breakdownSwitzerland: 301 citing papers, 2.2% of this breakdownNetherlands: 286 citing papers, 2.1% of this breakdown
0%24.1%Other 21.1%

Institutions

Fields

  • Medicine62.7%
  • Biochemistry, Genetics and Molecular Biology28.5%
  • Immunology and Microbiology5.7%
  • Computer Science0.8%
  • Engineering0.5%
  • Neuroscience0.4%
  • Other1.4%

Topics

  • Cancer Immunotherapy and Biomarkers16.2%
  • Gut microbiota and health7.1%
  • Lung Cancer Treatments and Mutations6.6%
  • Immunotherapy and Immune Responses3.7%
  • Cancer Genomics and Diagnostics3.6%
  • Lung Cancer Research Studies3.6%
  • Other59.2%

Coauthors

All papers

Open in search
  1. Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

    Authors: Bertrand Routy, Emmanuelle Le Chatelier, Lisa Derosa, Connie P.M. Duong, Maryam Tidjani Alou, Romain Daillère, Aurélie Fluckiger, Meriem Messaoudene, Conrad Rauber, María Paula Roberti, Marine Fidelle, Caroline Flament, Vichnou Poirier-Colame, Paule Opolon, Christophe Klein, Kristina Iribarren, Laura Mondragón, Nicolas Jacquelot, Bo Qu, Gladys Ferrere, Céline Clémenson, Laura Mezquita, J. Remon Masip, Charles Naltet, Solenn Brosseau, Courèche Kaderbhaï, Corentin Richard, Hira Rizvi, Florence Levenez, Nathalie Galleron, Benoît Quinquis, Nicolas Pons, Bernhard Ryffel, Véronique Minard-Colin, Patrick Gonin, Jean‐Charles Soria, Éric Deutsch, Yohann Loriot, François Ghiringhelli, Gérard Zalcman, François Goldwasser, Bernard Escudier, Matthew D. Hellmann, Alexander Eggermont, Didier Raoult, Laurence Albigès, Guido Kroemer, Laurence Zitvogel - Science 2017 cited by 5,594

  2. STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma

    Authors: Ferdinandos Skoulidis, Michael E. Goldberg, Danielle Greenawalt, Matthew D. Hellmann, Mark M. Awad, Justin F. Gainor, Alexa B. Schrock, Ryan J. Hartmaier, Sally E. Trabucco, Laurie M. Gay, Siraj M. Ali, Julia A. Elvin, Gaurav Singal, Jeffrey S. Ross, David Fabrizio, Péter M. Szabó, Chang Han, Ariella Sasson, Sujaya Srinivasan, Stefan Kirov, Joseph D. Szustakowski, Patrik Vitazka, Robin Edwards, José A. Bufill, Neelesh Sharma, Sai‐Hong Ignatius Ou, Nir Peled, David R. Spigel, Hira Rizvi, Elizabeth Jiménez Aguilar, Brett W. Carter, Jeremy Erasmus, Darragh Halpenny, Andrew J. Plodkowski, Niamh M. Long, Mizuki Nishino, Warren L. Denning, Ana Galán‐Cobo, Haïfa Hamdi, Taghreed Hirz, Pan Tong, Jing Wang, Jaime Rodriguez‐Canales, Pamela Villalobos, Edwin R. Parra, Neda Kalhor, Lynette M. Sholl, Jennifer L. Sauter, Achim A. Jungbluth, Mari Mino–Kenudson, Roxana Azimi, Yasir Y. Elamin, Jianjun Zhang, Giulia C. Leonardi, Fei Jiang, Kwok‐Kin Wong, J. Jack Lee, Vassiliki A. Papadimitrakopoulou, Ignacio I. Wistuba, Vincent A. Miller, Garrett M. Frampton, Jedd D. Wolchok, Alice T. Shaw, Pasi A. Jänne, Philip J. Stephens, Charles M. Rudin, William J. Geese, Lee A. Albacker, John V. Heymach - Cancer Discovery 2018 cited by 1,604

  3. Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer

    Authors: R. Vanguri, Jia Luo, Andrew Aukerman, Jacklynn V. Egger, Christopher J. Fong, Natally Horvat, Andrew Pagano, José de Arimateia Batista Araújo-Filho, Luke Geneslaw, Hira Rizvi, Ramon E. Sosa, Kevin Boehm, Soo‐Ryum Yang, Francis M. Bodd, Katia Ventura, Travis J. Hollmann, Michelle S. Ginsberg, Jianjiong Gao, R. Vanguri, Matthew D. Hellmann, Jennifer L. Sauter, Sohrab P. Shah - Nature Cancer 2022 cited by 361

  4. Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction

    Authors: Daniel K. Wells, Marit M. van Buuren, Kristen K. Dang, Vanessa M. Hubbard-Lucey, Kathleen C. F. Sheehan, Katie M. Campbell, Andrew Lamb, Jeffrey P. Ward, John Sidney, Ana-Belén Blázquez, Andrew J. Rech, Jesse M. Zaretsky, Begonya Comin-Anduix, Alphonsus H. C. Ng, William Chour, Thomas Yu, Hira Rizvi, Jia M. Chen, Patrice Manning, Gabriela Steiner, Xengie Doan, Aly A. Khan, Amit A. Lugade, Ana Mijalkovic Lazic, Angela Frentzen, Arbel D. Tadmor, Ariella Sasson, Arjun A. Rao, Baikang Pei, Barbara Schrörs, Beata Berent-Maoz, Beatriz M. Carreno, Bin Song, Bjoern Peters, Bo Li, Brandon W. Higgs, Brian J. Stevenson, Christian Iseli, Christopher A. Miller, Christopher Morehouse, Cornelis J.M. Melief, Cristina Puig-Saus, Daphne M. van Beek, David Balli, David Gfeller, David Haussler, Dirk Jäger, Eduardo Cortes, Ekaterina Esaulova, Elham Sherafat, Francisco Arcila, Gábor Bartha, Geng Liu, George Coukos, Guilhem Richard, Chang Han, Han Si, Inka Zörnig, Ioannis Xénarios, Ion Măndoiu, Irsan Kooi, James Conway, Jan H. Kessler, Jason Greenbaum, Jason Perera, Jason Harris, Jasreet Hundal, Jennifer Shelton, Jianmin Wang, Jiaqian Wang, Joel Greshock, Jonathon Blake, Joseph D. Szustakowski, Julia Kodysh, Juliet Forman, Lei Wei, Leo J. Lee, Lorenzo F. Fanchi, Maarten Slagter, Maren Lang, Markus S. Mueller, Martin Löwer, Mathias Vormehr, Maxim N. Artyomov, Michael Kuziora, Michael F. Princiotta, Michal Bassani‐Sternberg, Mignonette H. Macabali, Milica Kojicic, Naibo Yang, Nevena Ilic Raicevic, Nicolas Guex, Nicolas Robine, Niels Halama, Nikola Skundric, Ognjen Milićević, Pascal Gellert, Patrick Jongeneel, Pornpimol Charoentong, Pramod K. Srivastava and 45 more - Cell 2020 cited by 550

  5. Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing

    Authors: Hira Rizvi, Francisco Sánchez-Vega, Konnor La, Walid K. Chatila, Philip Jonsson, Darragh Halpenny, Andrew J. Plodkowski, Niamh M. Long, Jennifer L. Sauter, Natasha Rekhtman, Travis J. Hollmann, Kurt A. Schalper, Justin F. Gainor, Ronglai Shen, Ai Ni, Kathryn C. Arbour, Taha Merghoub, Jedd D. Wolchok, Alexandra Snyder, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Nicholas D. Socci, Michael F. Berger, Barry S. Taylor, Ahmet Zehir, David B. Solit, Maria E. Arcila, Marc Ladanyi, Gregory J. Riely, Nikolaus Schultz, Matthew D. Hellmann - Journal of Clinical Oncology 2018 cited by 1,421

  6. Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status

    Authors: Biagio Ricciuti, Kathryn C. Arbour, W. Marston Linehan, Amir Vajdi, Natalie I. Vokes, Lingzhi Hong, Jianjun Zhang, Michael Tolstorukov, Yvonne Y. Li, Liam F. Spurr, Andrew D. Cherniack, Gonzalo Recondo, Giuseppe Lamberti, Xinan Wang, Deepti Venkatraman, Joao V. Alessi, Victor R. Vaz, Hira Rizvi, Jacklynn V. Egger, Andrew J. Plodkowski, S. Khosrowjerdi, Subba R. Digumarthy, Hyesun Park, Nuno Vaz, Mizuki Nishino, Lynette M. Sholl, David A. Barbie, Mehmet Altan, John V. Heymach, Ferdinandos Skoulidis, Justin F. Gainor, Matthew D. Hellmann, Mark M. Awad - Journal of Thoracic Oncology 2021 cited by 367

  7. Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels

    Authors: Biagio Ricciuti, Xinan Wang, Joao V. Alessi, Hira Rizvi, Navin R. Mahadevan, Yvonne Y. Li, Andrew Polio, James Lindsay, Renato Umeton, Rileen Sinha, Natalie I. Vokes, Gonzalo Recondo, Giuseppe Lamberti, Marissa Lawrence, Victor R. Vaz, Giulia C. Leonardi, Andrew J. Plodkowski, Hersh Gupta, Andrew D. Cherniack, Michael Tolstorukov, Bijaya Sharma, Kristen D. Felt, Justin F. Gainor, Arvind Ravi, Gad Getz, Kurt A. Schalper, Brian S. Henick, Patrick M. Forde, Valsamo Anagnostou, Pasi A. Jänne, Eliezer M. Van Allen, Mizuki Nishino, Lynette M. Sholl, David C. Christiani, Xihong Lin, Scott J. Rodig, Matthew D. Hellmann, Mark M. Awad - JAMA Oncology 2022 cited by 384

  8. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer

    Authors: Lisa Derosa, Matthew D. Hellmann, Marco Spaziano, Darragh Halpenny, Marine Fidelle, Hira Rizvi, Niamh M. Long, Andrew J. Plodkowski, Kathryn C. Arbour, Jamie E. Chaft, J.A. Rouche, Laurence Zitvogel, Gérard Zalcman, Laurence Albigès, Bernard Escudier, Bertrand Routy - Annals of Oncology 2018 cited by 871

  9. Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy

    Authors: Jarushka Naidoo, Xuan Wang, Kaitlin M. Woo, Tunç Iyriboz, Darragh Halpenny, Jane Cunningham, Jamie E. Chaft, Neil H. Segal, Margaret K. Callahan, Alexander M. Lesokhin, Jonathan E. Rosenberg, Martin H. Voss, Charles M. Rudin, Hira Rizvi, Xue Hou, Katherine Rodríguez, Melanie Albano, Ruth-Ann Gordon, Charles Leduc, Natasha Rekhtman, Bianca Harris, Alexander M. Menzies, Alexander Guminski, Matteo S. Carlino, Benjamin Y. Kong, Jedd D. Wolchok, Michael A. Postow, Georgina V. Long, Matthew D. Hellmann - Journal of Clinical Oncology 2016 cited by 1,196

  10. Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer

    Authors: Kathryn C. Arbour, Laura Mezquita, Niamh M. Long, Hira Rizvi, Édouard Auclin, Ai Ni, Gala Martínez-Bernal, Roberto Ferrara, W. Victoria Lai, Lizza Hendriks, Joshua K. Sabari, Caroline Caramella, Andrew J. Plodkowski, Darragh Halpenny, Jamie E. Chaft, David Planchard, Gregory J. Riely, Benjamin Besse, Matthew D. Hellmann - Journal of Clinical Oncology 2018 cited by 1,053

  11. Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer

    Authors: Matthew D. Hellmann, Tavi Nathanson, Hira Rizvi, Ben Creelan, Francisco Sánchez-Vega, Arun Ahuja, Ai Ni, Jacki B. Novik, Levi Mangarin, Mohsen Abu-Akeel, Cailian Liu, Jennifer L. Sauter, Natasha Rekhtman, Eliza Chang, Margaret K. Callahan, Jamie E. Chaft, Martin H. Voss, Megan Tenet, Xuemei Li, Kelly L. Covello, Andrea Renninger, Patrik Vitazka, William J. Geese, Hossein Borghaei, Charles M. Rudin, Scott Antonia, Charles Swanton, Jeff Hammerbacher, Taha Merghoub, Nicholas McGranahan, Alexandra Snyder, Jedd D. Wolchok - Cancer Cell 2018 cited by 1,175

  12. Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR -Mutant Lung Cancer

    Authors: Adam J. Schoenfeld, Joseph M. Chan, Daisuke Kubota, Hiroki Sato, Hira Rizvi, Yahya Daneshbod, Jason C. Chang, Paul K. Paik, Michael Offin, Maria E. Arcila, Monika A. Davare, Ujwal Shinde, Dana Pe’er, Natasha Rekhtman, Mark G. Kris, Romel Somwar, Gregory J. Riely, Marc Ladanyi, Helena A. Yu - Clinical Cancer Research 2020 cited by 383

  13. Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer

    Authors: Arvind Ravi, Matthew D. Hellmann, Monica Arniella, Mark Holton, Samuel S. Freeman, Vivek Naranbhai, Chip Stewart, Ignaty Leshchiner, Jaegil Kim, Yo Akiyama, Aaron T. Griffin, Natalie I. Vokes, Mustafa Sakhi, Vashine Kamesan, Hira Rizvi, Biagio Ricciuti, Patrick M. Forde, Valsamo Anagnostou, Jonathan W. Riess, Don L. Gibbons, Nathan A. Pennell, Vamsidhar Velcheti, Subba R. Digumarthy, Mari Mino–Kenudson, Andrea Califano, John V. Heymach, Roy S. Herbst, Julie R. Brahmer, Kurt A. Schalper, Victor E. Velculescu, Brian S. Henick, Naiyer A. Rizvi, Pasi A. Jänne, Mark M. Awad, Andrew Chow, Benjamin D. Greenbaum, Marta Łuksza, Alice T. Shaw, Jedd D. Wolchok, Nir Hacohen, Gad Getz, Justin F. Gainor - Nature Genetics 2023 cited by 186

  14. Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes

    Authors: Michael Offin, Joseph M. Chan, Megan Tenet, Hira Rizvi, Ronglai Shen, Gregory J. Riely, Natasha Rekhtman, Yahya Daneshbod, Àlvaro Quintanal-Villalonga, Alexander Penson, Matthew D. Hellmann, Maria E. Arcila, Marc Ladanyi, Dana Pe’er, Mark G. Kris, Charles M. Rudin, Helena A. Yu - Journal of Thoracic Oncology 2019 cited by 448

  15. Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition

    Authors: Barzin Y. Nabet, Mohammad Shahrokh Esfahani, Everett J. Moding, Emily G. Hamilton, Jacob J. Chabon, Hira Rizvi, Chloé B. Steen, Aadel A. Chaudhuri, Chih Long Liu, Angela Bik‐Yu Hui, Diego Almanza, Henning Stehr, Linda Gojenola, Rene F. Bonilla, Michael C. Jin, Young-Jun Jeon, Diane Tseng, Cailian Liu, Taha Merghoub, Joel W. Neal, Heather A. Wakelee, Sukhmani K. Padda, Kavitha Ramchandran, Millie Das, Andrew J. Plodkowski, Christopher H. Yoo, Emily Chen, Ryan B. Ko, Aaron M. Newman, Matthew D. Hellmann, Ash A. Alizadeh, Maximilian Diehn - Cell 2020 cited by 369

  16. Lineage tracing reveals clonal progenitors and long-term persistence of tumor-specific T cells during immune checkpoint blockade

    Authors: Joy A. Pai, Matthew D. Hellmann, Jennifer L. Sauter, Marissa S. Mattar, Hira Rizvi, Hyung Jun Woo, Nisargbhai Shah, Evelyn M. Nguyen, Fathema Uddin, Àlvaro Quintanal-Villalonga, Joseph M. Chan, Parvathy Manoj, Viola Allaj, Marina K. Baine, Umesh Bhanot, Mala Jain, Irina Linkov, Fanli Meng, David Alan Brown, Jamie E. Chaft, Andrew J. Plodkowski, Mathieu Gigoux, Helen Won, Triparna Sen, Daniel K. Wells, Mark T.A. Donoghue, Elisa de Stanchina, Jedd D. Wolchok, Brian Houck‐Loomis, Taha Merghoub, Charles M. Rudin, Andrew Chow, Ansuman T. Satpathy - Cancer Cell 2023 cited by 139

  17. Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib

    Authors: Adam J. Schoenfeld, Kathryn C. Arbour, Hira Rizvi, Afsheen N. Iqbal, Shirish M. Gadgeel, Jeffrey Girshman, Mark G. Kris, Gregory J. Riely, Helena A. Yu, Matthew D. Hellmann - Annals of Oncology 2019 cited by 413

  18. Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer

    Authors: Danish Memon, Adam J. Schoenfeld, Darwin Ye, George Fromm, Hira Rizvi, Xiang H.-F. Zhang, Mohamed Reda Keddar, Divij Mathew, Kyung Jin Yoo, Jingya Qiu, Jayon Lihm, Jayalaksmi Miriyala, Jennifer L. Sauter, Jia Luo, Andrew Chow, Umesh Bhanot, Caroline G. McCarthy, Chad Vanderbilt, Cailian Liu, Mohsen Abu-Akeel, Andrew J. Plodkowski, Nicholas McGranahan, Marta Łuksza, Benjamin D. Greenbaum, Taha Merghoub, Ikbel Achour, J. Carl Barrett, Ross Stewart, Pedro Beltrão, Taylor H. Schreiber, Andy J. Minn, Martin L. Miller, Matthew D. Hellmann - Cancer Cell 2024 cited by 178

  19. Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression

    Authors: Esther Aguilar, Biagio Ricciuti, Justin F. Gainor, Kenneth L. Kehl, Sasha Kravets, Suzanne E. Dahlberg, Mizuki Nishino, Lynette M. Sholl, Anika E. Adeni, S. Subegdjo, S. Khosrowjerdi, Rachel Peterson, Subba R. Digumarthy, C. Liu, Jennifer L. Sauter, Hira Rizvi, Kathryn C. Arbour, B.W. Carter, John V. Heymach, Mehmet Altan, Matthew D. Hellmann, Mark M. Awad - Annals of Oncology 2019 cited by 336

  20. The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer

    Authors: Adam J. Schoenfeld, Chai Bandlamudi, Jessica A. Lavery, Joseph Montecalvo, Azadeh Namakydoust, Hira Rizvi, Jacklynn V. Egger, Carla P. Concepcion, Sonal Paul, Maria E. Arcila, Yahya Daneshbod, Jason C. Chang, Jennifer L. Sauter, Amanda Beras, Marc Ladanyi, Tyler Jacks, Charles M. Rudin, Barry S. Taylor, Mark T.A. Donoghue, Glenn Heller, Matthew D. Hellmann, Natasha Rekhtman, Gregory J. Riely - Clinical Cancer Research 2020 cited by 283

  21. The ectonucleotidase CD39 identifies tumor-reactive CD8+ T cells predictive of immune checkpoint blockade efficacy in human lung cancer

    Authors: Andrew Chow, Fathema Uddin, Michael Liu, Anton Dobrin, Barzin Y. Nabet, Levi Mangarin, Yonit Lavin, Hira Rizvi, Sam E. Tischfield, Àlvaro Quintanal-Villalonga, Joseph M. Chan, Nisargbhai Shah, Viola Allaj, Parvathy Manoj, Marissa S. Mattar, Maximiliano Meneses, Rebecca Landau, Mariana Ward, Amanda Kulick, Charlene Kwong, Matthew Wierzbicki, Jessica Yavner, Jacklynn V. Egger, Shweta S. Chavan, Abigail Farillas, Aliya Holland, Harsha Sridhar, Metamia Ciampricotti, Daniel Hirschhorn, Xiangnan Guan, Allison L. Richards, Glenn Heller, Jorge Mansilla‐Soto, Michel Sadelain, Christopher A. Klebanoff, Matthew D. Hellmann, Triparna Sen, Elisa de Stanchina, Jedd D. Wolchok, Taha Merghoub, Charles M. Rudin - Immunity 2022 cited by 126

  22. Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR -Mutant Lung Cancers

    Authors: Michael Offin, Hira Rizvi, Megan Tenet, Ai Ni, Francisco Sánchez-Vega, Bob T. Li, Alexander Drilon, Mark G. Kris, Charles M. Rudin, Nikolaus Schultz, Maria E. Arcila, Marc Ladanyi, Gregory J. Riely, Helena A. Yu, Matthew D. Hellmann - Clinical Cancer Research 2018 cited by 334

  23. Tim-4+ cavity-resident macrophages impair anti-tumor CD8+ T cell immunity

    Authors: Andrew Chow, Sara Schad, Michael D. Green, Matthew D. Hellmann, Viola Allaj, Nicholas Ceglia, Giulia Zago, Nisargbhai Shah, Sai Kiran Sharma, Marissa S. Mattar, Joseph M. Chan, Hira Rizvi, Hong Zhong, Cailian Liu, Yonina Bykov, Dmitriy Zamarin, Hongyu Shi, Sadna Budhu, Corrin A. Wohlhieter, Fathema Uddin, Aditi Gupta, Inna Khodos, Jessica Waninger, Angel Qin, Geoffrey J. Markowitz, Vivek Mittal, Vinod P. Balachandran, Jennifer N. Durham, Dung T. Le, Weiping Zou, Sohrab P. Shah, Andrew McPherson, Katherine S. Panageas, Jason S. Lewis, Justin S. A. Perry, Elisa de Stanchina, Triparna Sen, John T. Poirier, Jedd D. Wolchok, Charles M. Rudin, Taha Merghoub - Cancer Cell 2021 cited by 175

  24. Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC

    Authors: Fernando C. Santini, Hira Rizvi, Andrew J. Plodkowski, Ai Ni, Mario E. Lacouture, Maya Gambarin‐Gelwan, Olivia Wilkins, Elizabeth Panora, Darragh Halpenny, Niamh M. Long, Mark G. Kris, Charles M. Rudin, Jamie E. Chaft, Matthew D. Hellmann - Cancer Immunology Research 2018 cited by 332